Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.91)
# 587
Out of 5,126 analysts
45
Total ratings
57.89%
Success rate
10.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $62.24 | +52.63% | 1 | Dec 17, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $65 → $110 | $79.59 | +38.21% | 3 | Dec 11, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $5.83 | +157.29% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $1.51 | +429.80% | 2 | Nov 24, 2025 | |
| IMNM Immunome | Maintains: Overweight | $25 → $33 | $24.88 | +32.64% | 3 | Nov 17, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $13.48 | +11.28% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $9.37 | +92.10% | 4 | Nov 5, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $23.49 | +49.00% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $1.82 | +229.67% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $32.17 | +39.88% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $16.85 | +78.04% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $43.90 | +36.67% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $24.44 | +35.02% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $4.01 | +99.50% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $5.66 | +165.02% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.15 | +334.78% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $8.86 | +1,028.67% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.66 | +1,104.82% | 1 | May 14, 2024 |
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $62.24
Upside: +52.63%
Kymera Therapeutics
Dec 11, 2025
Maintains: Overweight
Price Target: $65 → $110
Current: $79.59
Upside: +38.21%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $5.83
Upside: +157.29%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $1.51
Upside: +429.80%
Immunome
Nov 17, 2025
Maintains: Overweight
Price Target: $25 → $33
Current: $24.88
Upside: +32.64%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $13.48
Upside: +11.28%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $9.37
Upside: +92.10%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $23.49
Upside: +49.00%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $1.82
Upside: +229.67%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $32.17
Upside: +39.88%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $16.85
Upside: +78.04%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $43.90
Upside: +36.67%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $24.44
Upside: +35.02%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $4.01
Upside: +99.50%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $5.66
Upside: +165.02%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.15
Upside: +334.78%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $8.86
Upside: +1,028.67%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.66
Upside: +1,104.82%